多组件反应推动了针对中枢神经系统病理的药物的发现和优化
Lucía Campos-Prieto1,2, Aitor García-Rey1,2, Eddy Sotelo1,2
1Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Beilstein journal of organic chemistry
|December 13, 2024
概括
多组分反应 (MCRs) 加快了对中枢神经系统 (CNS) 疾病 (如阿尔茨海默氏症和帕金森症) 的药物发现. 这次审查强调了MCRs.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 神经科学是一个神经科学.
背景情况:
- 发现有效的疾病治疗方法是一个重大的科学挑战.
- 多元组分反应 (MCR) 提供了各种化学库的高效合成.
- 对于时间高效和可持续的药物发现,MCRs是有价值的.
研究的目的:
- 审查MCRs在开发中枢神经系统 (CNS) 疾病的配体中的应用.
- 为突出重点研究阿尔茨海默病,帕金森病,精神分裂症,抑郁症和.
- 简要介绍当前的研究趋势和中枢神经系统病理的多重抗癌药物的突破.
主要方法:
- 文献综述专注于代表性研究.
- 对主要中枢神经系统病理应用的MCR方法的分析.
- 识别相关的药物标和已开发的配体.
主要成果:
- 已成功地使用MCR来生成用于CNS目标的多种连接体.
- 关键研究表明,MCRs在治疗阿尔茨海默氏症,帕金森症和其他神经系统疾病方面具有实用性.
- 具体的例子展示了有前途的治疗候选者的发展.
结论:
- 多重复合反应器是加速发现新型中枢神经系统疗法的强大工具.
- 审查的研究强调了MCRs在解决复杂神经疾病方面的潜力.
- 进一步利用MCR的研究对于推进中枢神经系统疾病的治疗方法至关重要.
相关概念视频
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Structure-Activity Relationships and Drug Design
554
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
554
Drugs Affecting Neurotransmitter Release or Uptake
947
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
947
Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194


